Open AccessAngiogenesis in gastrointestinal stromal tumors: From bench to bedside
Author(s) -
Stavros P. Papadakos,
Christos Tsagkaris,
Marios Papadakis,
Αndreas S. Papazoglou,
Dimitrios V. Moysidis,
Constantinos G Zografos,
Stamatios Theocharis
Publication year - 2022
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v14.i8.1469
Subject(s) - gist , medicine , angiogenesis , stromal cell , bench to bedside , repurposing , adverse effect , gastroenterology , oncology , medical physics , ecology , biology
Gastrointestinal stromal tumors (GISTs) are rare neoplasms with an estimated incidence from 0.78 to 1-1.5 patients per 1. They most commonly occur in the elderly during the eighth decade of life affecting predominantly the stomach, but also the small intestine, the omentum, mesentery and rectosigmoid. The available treatments for GIST are associated with a significant rate of recurrent disease and adverse events. Thorough understanding of GIST's pathophysiology and translation of this knowledge into novel regimens or drug repurposing is essential to counter this challenge. The present review summarizes the existing evidence about the role of angiogenesis in GIST's development and progression and discusses its clinical underpinnings.